Phase 2 Start~month

Phase 2 Start: A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe

Drug
ft819
Indication
Lupus Nephritis; Systemic Lupus Erythematosus; SLE - Systemic Lupus Erythematosus

Other upcoming events for FATE

Phase 3 ReadoutPhase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety
Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe
Phase 2 StartPhase 2 Start: Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor
Phase 3 ReadoutPhase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or
Phase 3 ReadoutPhase 3 Topline: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bev

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe — FATE Phase 2 Start | BioSniper